HEOR Medical Communications ProfessionalsDemonstrating Healthcare Value and Achieving Market Access Through Publication: This group addresses the rapidly-expanding need for qualified medical communications professionals or researchers who create communications tools that demonstrate product value, […]
New Newsletter from Manchester Centre for Health Economics
The Manchester Centre for Health Economics at The University of Manchester recently released its first newsletter, now available here. (Source: Manchester Centre for Health Economics,) […]
CER, HEOR, and Value-Based Frameworks in the US
This report addresses the following questions:- What impact have CER and HEOR had on drug reimbursement and uptake in the US so far? - Who are the key generators and users of CER and HEOR data? - How are new drug valuation frameworks such as ASCO, NCCN or ICER impacting drug reimbursement in the US? […]
Early-Registration for ISPOR’s BIA Training Ends Today!
Today is the last day to take advantage of the early registration rate for Building a Budget Impact Model: Budget Impact Analysis Training, ISPOR’s comprehensive in-person training program. Find out more here. (Source: ISPOR, 2016) […]
ICER to Partner with University of Colorado Skaggs School of Pharmacy
The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and the Institute for Clinical and Economic Review (ICER) have formed a partnership to leverage CU Skaggs School of Pharmacy’s expertise in economic modeling of pharmaceutical interventions to support ICER’s growing […]
Don’t Miss Out on This Essential HEOR Education
Looking to expand your knowledge and skill set? This intensive 2-day program will take you from basic knowledge of Budget Impact Analysis (BIA) through understanding how to build and manipulate your own BIA models! Join other professionals for, Building a Budget Impact Model: Budget Impact Analysis […]
340B Hospitals Making Huge Profits Off Medicare
The Office of Inspector General (OIG) released a report in December of 2015 on the 340B drug discount program which documents the tremendous profits earned by hospital outpatient departments from the Medicare Part B program. Find out more here. (Source: Adam Fein, Drug Channels, 9/1/16) […]
Price Spikes Put Diabetic Lives At Risk
After years of rapid price increases, millions of diabetes patients, dependent upon insulin, are not unable to afford their medication. Diabetes can not be controlled by limiting, or spreading out the insulin to make it last longer and the dangers of doing so are high. Read more here. (Source: […]
How Dangerous is Direct to Patient Advertising?
A recent article published in JAMA Oncology, discusses how the direct-to-consumer advertising of, specifically cancer related products, could be detrimental to patients and the physician-patient relationship by promoting misconceptions about efficacy and toxic effects of new therapies. Read more […]
Aetna’s Obamacare Surprise – Derailing American Healthcare
In April, Aetna's CEO was committed to stay in the ACA exchanges and was boasting on how the million or so new Obamacare customers they had acquire would have cost them around $1 billion. In July, the U.S. Justice Department challenges the proposed merger between Aetna and Humana, then receives a […]
You’ve Never Seen Philly Like This Before!
The Philadelphia Department of Public Health (PDPH) and the Office of Open Data and Digital Transformation, recently developed the web-based Community Health Explorer app. The tool provides a breadth of information on current demographic trends and will allow anyone to see and better understand the […]
ISPOR Invites You to the Upcoming Stakeholder’s Conference
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) upcoming Stakeholder's Conference on the Initiative on US Value Assessment Frameworks will be held in Washington DC on September 23, 2016. The conference will feature presentations and panel discussions involving […]
Don’t Miss These FirstWord Reports
FirstWord interviews and surveys over 9,000 pharma professionals, payers, physicians and clinical KOLs every year to bring you unrivalled actionable insight to drive competitive advantage. The following are a small sample:Innovations in Drug Pricing and Reimbursement (2016)Customer Experience (CX) […]
CMS Aims to Recoup $11B in Overpayments with New Rule
The Centers for Medicare & Medicaid (CMS), despite stakeholder opposed, recently released a final rule to keep a 1.5% cut to hospital reimbursement. Find out more here. (Source: Managed Health Care Connect, 8/4/16) […]
Winners of the Article-of-the-Year Award Announced
The John M Eisenberg Article-of-the-Year Award recognizes excellence and original research in health services research, and was recently awarded to Guy David PhD and Candace Gunnarsson EdD, for their award winning article, Do Patient-Centered Medical Homes Reduce Emergency Department Visits?. See […]
JCER Sees Increase in Impact Factor
The Journal of Comparative Effectiveness Research has seen its impact factor increase over this past year. Their most recent publication, Volume 5, Issue 4 is now available online, here. (Source: Future Medicine, 2016) […]
Clinical Pathways Congress to address value-based care, including the appropriate and cost-effective utilization of cancer drugs
Organized by Journal of Clinical Pathways, the Clinical Pathways Congress, September 16-18, Boston, MA, brings together stakeholders–payers, providers, administrators and HEOR specialists–to discuss value-based management tools for cancer treatment, cost-effective therapies and questions regarding […]
Is FDAMA Section 114 Ready to Live Up to its Promise?
The U.S. Food and Drug Administration (FDA) recently announced plans to release guidance on implementing Section 114 of the Food and Drug Administration Modernization Act (FDAMA). Find out more about AMCP's suggestions here. (Source: AMCP, 6/24/16) […]
HEOR Today and in the Future
Jennifer Fillman, FP General Manager Specialty Services Cardinal Health Specialty Solutions, recently sat down with Ronda Copher, PhD, Director of Health Economics and Outcomes Research (HEOR) at Eisai Inc. to discuss some of the latest trends in the field of HEOR, ranging from the challenges of […]
HE.Com Connecting the Right People with the Right Jobs
Make sure to mark Wednesday, July 20, 2016 down on your calendar and get ready for the HealthEconomics.Com HEOR Career Fair.Employers- hire better, hire faster, hire more cost-effectively.Job Seekers- connect with industry leaders for global positions, attendance is free and available anywhere you […]
Building Effective Health Economic Outcomes Research (HEOR) Teams
This FirstWord expert report analyses the growing pressure points on HEOR teams and identifies the essential staff talents, organisational positioning, external providers and evaluation criteria needed to deliver persuasive HEOR in a demanding market. Available for purchase here. (Source: FirstWord, […]
Grow Your Business with HealthEconomics.Com
HealthEconomics.Com is your single global link to the Pharma and Payer health economics & outcomes research (HEOR) and market access stakeholder communities. Take a look at this short video and find out how HealthEconomics.Com can help you grow your business, here. (Source: HealthEconomics.Com, […]
Call for Abstracts – ISPOR 19th Annual European Congress
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is now inviting submissions for the 19th Annual European Congress, to be held October 29- November 2, in Vienna, Austria. Abstract Submission Deadline is June 21, 2016. More details and submission instructions are […]
Why the U.S. Needs Better Health Care Economics Education
A recent blog post on tHEORetically Speaking talks about the need for better health care economics education in the United States. There are presently very few academic programs available in the U.S., designed specifically to equip professionals with a comprehensive grounding in both health care and […]
6 Ways Trumpcare Differs From Obamacare?
How does Trumps healthcare plan differ from Obamacare? See six key differences here. (Source: Joseph Mack, Managed Healthcare Executive, 4/19/16) […]
A Closer Look at Cancer Drug Value Assessment Tools
Both the ASCO and the NCCN have recently made attempts to address the affordability issue in cancer care and measure the value of cancer therapies. Learn more about the offerings and limitations of these oncology value tools here. (Source: Jennifer Chang, Managed Healthcare Executive, 4/20/16) […]
Do Higher Prices Translate into Greater Perceived Effectiveness?
Manufacturers set prices that best represent their products value, but do higher prices really translate into greater perceived therapeutic effectiveness with payers? Learn more here. (Source: Journal of Clinical Pathways, April 2016) […]
Does Society Place Special Value on End of Life Treatments?
Care at the End of Life: An Economic Perspective, is a book edited by Jeff Round of the University of Bristol and features contributions from a variety of health economists, including OHE's Koonal Shah. Learn more here. (Source: OHE, 4/6/16) […]
PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?
The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to […]
How Should Economists Present Economic Evaluations for Policymakers?
What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review is now available for purchase here. Objective: to systematically review health economic guidelines for information on how to present health economic evaluations and consider implications […]
